Clinical trials
Tuberculosis trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Unknown status | 3 |
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| ASST Fatebenefratelli Sacco | 2 |
| Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria | 1 |
| Azienda Ospedaliera San Gerardo di Monza | 1 |
| BioMérieux | 1 |
| Eleonora Nucera | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
| Hospital Universitario 12 de Octubre | 1 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 1 |
| Maggiore Bellaria Hospital, Bologna | 1 |
| Ospedale San Raffaele | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tuberculosis | 17 |
| Latent Tuberculosis | 5 |
| Lung Neoplasms | 4 |
| Pneumonia | 3 |
| Sarcoidosis | 3 |
| Disease | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Arthritis, Rheumatoid | 1 |
| Bronchiectasis | 1 |
| Bronchitis | 1 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.